Publications by authors named "Filipp Ianevski"
Introduction: Head and neck squamous cell carcinoma (HNSCC) is a common cancer with a five-year survival rate around 60%, indicating a need for new treatments. BH3 mimetics are small molecules that inhibit anti-apoptotic Bcl-2 family proteins, resulting in apoptosis induction.
Methods: We performed a high-throughput screen using a Myogel matrix to identify the synergy between irradiation and the novel BH3 mimetics A-1155463, A-1331852, and navitoclax in 12 HNSCC cell lines, normal (NOF) and cancer-associated fibroblasts (CAF), and dysplastic keratinocytes (ODA).
Article Synopsis
- Acute myeloid leukemia (AML) is a tough-to-treat blood cancer that requires drug combinations to improve efficacy, as single-drug treatments often fail.
- Researchers created a bipartite network from patient tumor samples and approved drugs to analyze treatment responses and identify effective combinations while considering both efficacy and toxicity.
- Their findings highlighted two promising drug combinations, ruxolitinib-ulixertinib and sapanisertib-LY3009120, which showed high effectiveness and low toxicity, paving the way for personalized AML treatments along with standard therapies.
Functional precision medicine (fPM) offers an exciting, simplified approach to finding the right applications for existing molecules and enhancing therapeutic potential. Integrative and robust tools ensuring high accuracy and reliability of the results are critical. In response to this need, we previously developed Breeze, a drug screening data analysis pipeline, designed to facilitate quality control, dose-response curve fitting, and data visualization in a user-friendly manner.
View Article and Find Full Text PDF